EMH Schweizerischer Ärzteverlag AG
Farnsburgerstrasse 8
CH-4132 Muttenz
+41 (0)61 467 85 44
support@swisshealthweb.ch
www.swisshealthweb.ch
EMH Schweizerischer Ärzteverlag AG
Farnsburgerstrasse 8
CH-4132 Muttenz
+41 (0)61 467 85 44
support@swisshealthweb.ch
www.swisshealthweb.ch
Atrial fibrillation (AF) has become the most common arrhythmia worldwide and its incidence is increasing. Treatment strategies for symptomatic patients include stroke prevention, management of cardiovascular comorbidities, and direct treatment of AF itself. With regard to interventional AF treatment, a novel technique called pulsed field ablation has emerged. Large registry data in more than 15,000 patients have demonstrated a high efficacy in reducing the burden of AF with a very high safety. This review provides an overview of the technical aspects of pulsed field ablation and the published clinical data.
This study describes the association between preoperative dental clearance and subsequent postoperative outcomes. We found no difference in all-cause mortality, incidence of postoperative endocarditis, postoperative infection and length of hospital stay after preoperative dental clearance before cardiac surgery. The current available evidence points to an unestablished association, leaving us without a clear understanding of whether preoperative dental clearance leads to a lower incidence of postoperative endocarditis.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a fatal rare inherited cardiac channelopathy. Affected patients are susceptible to develop deadly ventricular arrythmias after physical or emotional stress. The typical arrhythmia presents as bidirectional and/or polymorphic ventricular tachycardias. To illustrate the clinical challenges in properly diagnosing this disease, we report two cases of CPVT together with a brief literature review.
Sarcoidosis is a multisystemic, chronic inflammatory disorder involving lymph nodes and lungs characterized by a non-caseating, epithelioid cell granulomatous inflammation of affected organs. Cardiac involvement has been reported in 5-30% depending on the diagnostic criteria.
Thrombosis remains a significant clinical challenge with potential life-threatening consequences. Despite advancements in anticoagulants, concerns about bleeding and the delicate balance of thrombotic risks persist, especially in patients with specific comorbidities such as renal insufficiency, cirrhosis, and those with medical devices. The search for effective anticoagulant therapies that can prevent thrombotic events while minimizing bleeding risks, has led to the emergence of factor XI (FXI) inhibition as a promising approach.